- Price
- $211.04
- Day
- -3.19%
- Mkt Cap
- $10.86B
- 52W Range
- $96.09 – $260.19
- Volume
- 955.2K
- Beta
- 0.60
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 31st
BLND, AXSM and BCML have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2026.
New Strong Sell Stocks for July 29th
ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM
Caxton Associates LLP bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,311 shares of the company's stock, valued at approximately $729,000. Other hedge funds have also made changes to their positions in
New Strong Sell Stocks for July 27th
LEN, AXSM and SAM have been added to the Zacks Rank #5 (Strong Sell) List on July 27, 2026.